FDA sends warning letter to CBD company Curaleaf

Amid growing confusion over how to regulate the booming CBD industry, the FDA is warning Massachusetts-based Curaleaf not to make unsubstantiated health claims about the CBD products it sells. In a letter made public yesterday, the FDA said that Curaleaf, which operates in 12 states, was illegally selling CBD products with claims that they would treat cancer, Alzheimer’s disease, and other conditions. “There are many unanswered questions about the science, safety, effectiveness and quality of unapproved products containing CBD,” acting FDA commissioner Dr. Ned Sharpless said in a statement. Curaleaf said in a statement that it plans to respond to the FDA within 15 days and is “fully committed to complying with FDA requirements for all of the products that it markets.”